Patents Assigned to INSTIL BIO (UK) LIMITED
-
Patent number: 11945876Abstract: Some embodiments provided herein are chimeric costimulatory antigen receptor (CoStAR), useful in adoptive cell therapy (ACT), and cells comprising the CoStAR. In some embodiments, the CoStAR can act as a modulator of cellular activity enhancing responses to defined antigens. In some embodiments, CoStAR and/or fusion proteins, nucleic acids encoding the CoStAR and therapeutic uses thereof are also provided.Type: GrantFiled: June 15, 2022Date of Patent: April 2, 2024Assignees: Instil Bio (UK) Limited, Instil Bio, Inc.Inventors: John Bridgeman, Robert Hawkins, Ruben Rodriguez, Gray Kueberuwa, Milena Kalaitsidou
-
Publication number: 20240018476Abstract: The present invention provides methods for isolating and cryopreserving tumor infiltrating lymphocytes (TILs) and producing therapeutic populations of TILs, including methods via use of a kit and a semi-automatic device for aseptic disaggregation, enrichment, and cryopreservation of a resected tumor prior to expansion of the TIL population. The present invention also provides methods for expansion, and/or stabilization of TILs, for instance UTILs, compositions involving the same and methods of treatment involving the same.Type: ApplicationFiled: May 9, 2023Publication date: January 18, 2024Applicant: INSTIL BIO (UK) LIMITEDInventors: Ryan Guest, Joanne MCCAFFREY
-
Patent number: 11767510Abstract: The present invention provides methods for isolating and cryopreserving tumor infiltrating lymphocytes (TILs) and producing therapeutic populations of TILs, including methods via use of a kit and a semi-automatic device for aseptic disaggregation, enrichment, and cryopreservation of a resected tumor prior to expansion of the TIL population. The present invention also provides methods for expansion, and/or stabilization of TILs, for instance UTILs, compositions involving the same and methods of treatment involving the same.Type: GrantFiled: April 29, 2022Date of Patent: September 26, 2023Assignee: INSTIL BIO (UK) LIMITEDInventors: Ryan Guest, Joanne McCaffrey
-
Patent number: 11697677Abstract: The present invention relates to a chimeric molecule useful in adoptive cell therapy (ACT), and cells comprising the same. The chimeric molecule can act as a modulator of cellular activity enhancing responses when an endogenous T-cell receptor (TCR) is engaged with its cognate antigen. The present invention also provides proteins, nucleic acids encoding the chimeric molecule and therapeutic uses thereof.Type: GrantFiled: August 25, 2022Date of Patent: July 11, 2023Assignee: INSTIL BIO (UK) LIMITEDInventors: John Bridgeman, Robert Hawkins, Ruben Rodriguez, Sujita Sukumaran, Xingliang Zhou, Eric Gschweng
-
Patent number: 11618878Abstract: The present invention concerns a single use aseptic kit comprising: a disaggregation module for receipt and processing of material comprising solid mammalian tissue; and a stabilisation module for storing disaggregated product material, wherein each of said modules comprises one or more flexible containers connected by one or more conduits adapted to enable flow of the tissue material there between; and wherein each of said modules comprises one or more ports to permit aseptic input of media and/or reagents into the one or more flexible containers. The invention further relates to an automated device for semi-automated aseptic disaggregation and/or enrichment and/or stabilisation of cells or cell aggregates from mammalian solid tissue comprising a programmable processor and the single use aseptic kit. The invention further relates to a semi-automatic aseptic tissue processing method.Type: GrantFiled: May 26, 2022Date of Patent: April 4, 2023Assignee: INSTIL BIO (UK) LIMITEDInventor: Ryan Dominic Guest
-
Patent number: 11618877Abstract: The present invention concerns a single use aseptic kit comprising: a disaggregation module for receipt and processing of material comprising solid mammalian tissue; and a stabilisation module for storing disaggregated product material, wherein each of said modules comprises one or more flexible containers connected by one or more conduits adapted to enable flow of the tissue material there between; and wherein each of said modules comprises one or more ports to permit aseptic input of media and/or reagents into the one or more flexible containers. The invention further relates to an automated device for semi-automated aseptic disaggregation and/or enrichment and/or stabilisation of cells or cell aggregates from mammalian solid tissue comprising a programmable processor and the single use aseptic kit. The invention further relates to a semi-automatic aseptic tissue processing method.Type: GrantFiled: May 26, 2022Date of Patent: April 4, 2023Assignee: INSTIL BIO (UK) LIMITEDInventor: Ryan Dominic Guest
-
Patent number: 11530386Abstract: The present invention discloses cell lines and recombinant growth factor receptors useful in adoptive cell therapy (ACT), wherein the recombinant growth factor receptor can act as a molecular switch enabling cells expressing the rGFR protein to be expanded in-vitro or in- vivo. Thus the invention provides a T or NK cell, comprising a recombinant growth factor receptor (rGFR) comprising: (i) an extracellular (EC) domain; (ii) a thrombopoietin receptor transmembrane (TM) domain; and (iii) a growth factor receptor intracellular (IC) domain.Type: GrantFiled: December 15, 2016Date of Patent: December 20, 2022Assignee: INSTIL BIO (UK) LIMITEDInventor: John Stephen Bridgeman